Experimental oral therapy PrimeC shows safety and signals of clinical benefit in ALS

Name: Experimental oral therapy PrimeC shows safety and signals of clinical benefit in ALS
Start: 2026-03-16T15:00:04.000Z
Location: Boston

drug approval expired 92% Health

A phase 2b clinical trial of PrimeC, an experimental oral therapy for ALS, found the drug to be safe and well-tolerated, with exploratory signals suggesting potential clinical benefit. The PARADIGM study, conducted by Mass General Brigham and Barrow Neurological Institute, was published in JAMA Neurology.

🇺🇸 Location: Boston — Sources: 1 — First seen: 2026-03-16 — Last seen: 2026-03-16

ALS PrimeC clinical trial neurology PARADIGM study

Contributing Articles

Experimental oral therapy PrimeC shows safety and signals of clinical benefit in ALS
Medical Xpress — 2026-03-16